The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface h
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. For example, the present invention describes nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.
대표청구항▼
1. A composition comprising: (1) synthetic nanocarriers having at least one surface, wherein a first surface of the synthetic nanocarriers comprises an immunofeature surface comprising a plurality of nicotine moieties,wherein the immunofeature surface binds to antigen presenting cells with high avid
1. A composition comprising: (1) synthetic nanocarriers having at least one surface, wherein a first surface of the synthetic nanocarriers comprises an immunofeature surface comprising a plurality of nicotine moieties,wherein the immunofeature surface binds to antigen presenting cells with high avidity and low affinity as compared to an antibody that is specific for an antigen presenting cell-expressed surface antigen; and(2) a pharmaceutically acceptable excipient. 2. The composition of claim 1, wherein the composition further comprises an immunostimulatory agent, wherein the immunostimulatory agent: (i) is associated with the immunofeature surface: (ii) is associated with a second surface of the nanocarrier; or (iii) is encapsulated within the nanocarrier. 3. The composition of claim 1, wherein the synthetic nanocarriers are capable of activating CD4+ T cells, NKT cells, or both when administered to a human. 4. The composition of claim 1, wherein the synthetic nanocarriers are capable of stimulating production of anti-nicotine IgG antibodies when administered to a human. 5. The composition of claim 1, wherein the synthetic nanocarriers are capable of eliciting a immoral immune response in a human subject. 6. The composition of claim 1, wherein, when the synthetic nanocarriers are administered to a human subject, the synthetic nanocarriers are capable of being translocated across a subcapsular sinus (SCS) floor by SCS macrophages in the subject. 7. The composition of claim 2, wherein the immunostimulatory agent is selected from a TLR agonist, an interleukin, an interferon, a cytokine, and an adjuvant. 8. The composition of claim 1, wherein the synthetic nanocarriers comprises polymer molecules, and wherein the plurality of nicotine moieties are covalently attached to the polymer molecules. 9. The composition of claim 8, wherein the plurality of nicotine moieties are (S)-(−)-nicotine moieties, and wherein the synthetic nanocarriers comprise a polymer having the structure of formula (I) (X)n-L1-(Y)m-L2-A wherein: (I)X is a hydrophobic polymer segment; Y is a hydrophilic polymer segment; n and m are selected from 0 and 1, provided that n and m are not both 0; L1 and L2 are independently selected from a bond and a linking group; and A is (S)-(−)-nicotine. 10. The composition of claim 8, wherein the plurality of nicotine moieties comprises (S)-(−)-nicotine having the structure wherein one of R1-R7 represents the polymer, and the others are selected from H, alkyl, aryl, alkoxy, aryloxy, alkaryl, and aralkyl, any of which may be substituted or unsubstituted and may contain one or more heteroatoms; andwherein R8 is an alkyl group. 11. The composition of claim 1, wherein the plurality of nicotine moieties are present in a density equal to or greater than the density required to obtain at least 10% of the maximal immobilization observed for a monoclonal antibody (MAb) in an antigen presenting cell (APC) binding assay, provided that, in the APC binding assay, the half maximal binding density for the plurality of moieties is at least twice the half maximal binding density for the MAb. 12. The composition of claim 11, wherein the plurality of nicotine moieties are present in a density equal to or greater than the density required to obtain at least 20% of the maximal immobilization observed for a MAb in the APC binding assay. 13. The composition of claim 11, wherein the half maximal binding density for the plurality of moieties is at least four times the half maximal binding density for the MAb. 14. The composition of claim 11, wherein the APC binding assay comprises: (a) preparing a series of substrates having coatings of a functional moiety at a series of surface coating densities, wherein the functional moiety is capable of binding to dendritic cell (DC)or subcapsular sinus macrophage surface receptors;(b) exposing the series of substrates to single-cell suspensions of DCs or subcapsular sinus macrophages for a predetermined period of time;(c) removing non-adhered APCs front the series of substrates, and fixing the adhered APCs to the series of substrates;(d) quantifying the number of adhered APCs per unit surface area for each substrate in the series of substrates;(e) plotting the result from (d) against the coating density of the functional moiety;(f) obtaining a value for the maximal immobilization by determining the maximum number of adhered APCs per unit surface area for the series of substrates; and(g) obtaining a value for half maximal binding density by determining the surface coating density that provides 50% of the maximum. 15. The composition of claim 11, wherein the MAb is anti-CD1c (BDCA-I) Clone AD5-8E7 or rat anti-mouse CD169 clone 3D6.112. 16. The composition of claim 1, wherein the nicotine comprises a derivative, metabolite, or analog of nicotine. 17. A method comprising administering to a subject an initial dose of the composition of claim 1. 18. The method of claim 17, wherein the subject has not been previously vaccinated against nicotine, wherein a post-administration anti-nicotine antibody peak concentration in the subject is greater than or equal to 100 ng/ml. 19. The method of claim 17 further comprising-administering to the subject a first subsequent dose of the composition of claim 1 at a time period after the administration of the initial dose. 20. The method of claim 19, wherein the time period after the administration of the initial dose is between 1 day and 1 year. 21. The method of claim 19, further comprising administering to the subject a second subsequent dose of the composition of claim 1 at a time period after the administration of the first subsequent dose. 22. The method of claim 21, wherein the time period after the administration of the first subsequent dose is between 1 day and 1 year. 23. A composition comprising: (1) synthetic nanocarriers having at least one surface, wherein a first surface of the synthetic nanocarriers comprises a plurality of nicotine moieties in an amount effective to provide a humoral response to the nicotine moieties; and(2) a pharmaceutically acceptable excipient. 24. The composition of claim 23, wherein the nicotine moieties are present in an amount effective to provide avidity-based binding to binding to mammalian antigen presenting cells. 25. The composition of claim 23, wherein the diameter of the nanocarriers is greater than 100 nm. 26. The composition of claim 23, wherein the pharmaceutically acceptable excipient is selected from solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and lubricants. 27. The composition of claim 23, wherein the composition targets a subcapsular sinus macrophage. 28. The composition of claim 23, wherein the composition targets a dendritic cell. 29. The composition of claim 23, wherein the composition does not substantially activate complement. 30. The method of claim 17, wherein administration of the composition elicits a humoral immune response. 31. The method of claim 17, wherein the-subject has a baseline IgG anti-nicotine antibody serum concentration of less than 100 ng/ml, wherein a post-administration anti-nicotine IgG antibody peak serum concentration in the subject is more than 200 ng/ml.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (192)
Gerster John F. (Woodbury MN) Crooks Stephen L. (Mahtomedi MN) Lindstrom Kyle J. (Houlton WI), 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines.
Schmitz,Juergen; Dzionek,Andrzej; Buck,David William, Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby.
Arimilli Murty N. ; Cundy Kenneth C. ; Dougherty Joseph P. ; Kim Choung U. ; Oliyai Reza ; Stella Valentino J., Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Mikos Antonios G. (Houston TX) Sarakinos Georgios (Boston MA) Vacanti Joseph P. (Winchester MA) Langer Robert S. (Newton MA) Cima Linda G. (Lexington MA), Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures.
Barrera Denise (Oakdale MN) Langer Robert S. (Newton MA) Lansbury ; Jr. Peter T. (Brookline MA) Vacanti Joseph P. (Winchester MA), Biodegradable polymers for cell transplantation.
Vacanti Joseph P. ; Vacanti Charles A. ; Langer Robert S., Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous struct.
D\Amore Patricia (Brookline MA) Leong Kam W. (Cambridge MA) Langer Robert S. (Somerville MA), Bioerodible articles useful as implants and prostheses having predictable degradation rates.
Skwierczynski Raymond D. ; Phares Kenneth R. ; Miller Richard L. ; Li Zheng Jane ; Jozwiakowski Michael J. ; Busch Terri F., Formulations and methods for treatment of mucosal associated conditions with an immune response modifier.
Dalton,James T.; Miller,Duane D.; Steiner,Mitchell S.; Veverka,Karen A., Halogenated selective androgen receptor modulators and methods of use thereof.
Swain Philip A. ; Schad Victoria C. ; Greenstein Julia L. ; Exley Mark A. ; Fox Barbara S. ; Powers Stephen P. ; Gefter Malcolm L., Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same.
Kedl,Ross M.; Griesgraber,George W.; Zarraga,Isidro Angelo E.; Wightman,Paul D., Immunostimulatory compositions and methods of stimulating an immune response.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
Bengs, Holger; Grande, Jürgen; Schuth, Silke; Böhm, Gitte; Schneller, Arnold; Brunner, Anette, Method for preparing smooth-surface spherical microparticles completely or partially made of at least one water-insoluble linear polysaccharide and microparticles produced according to this method.
Bomberger David C. ; Catz Paul G. ; Smedley Mark I. ; Stearns Paul C., Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced.
Deming, Timothy J.; Yu, Miaoer; Curtin, Scott A.; Hwang, Jungyeon; Wyrsta, Michael D.; Nowak, Andrew; Seidel, Scott W., Methods and compositions for controlled polypeptide synthesis.
Speaker Tully J. (Philadelphia PA) Sultzbaugh Kenneth J. (Philadelphia PA), Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses.
Jacobson Stephen C. ; Ramsey J. Michael, Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same.
Horoszewicz Julius S. (Williamsville NY), Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A.; Garimella, Viswanadham; Li, Zhi, Nanoparticles having oligonucleotides attached thereto and uses therefor.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Bischofberger Norbert W. ; Jones Robert J. ; Arimilli Murty N. ; Lin Kuei-Ying ; Louie Michael S. ; McGee Lawrence R. ; Prisbe Ernest J. ; Lee William A. ; Cundy Kenneth C., Nucleotide analogs.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Fessi Curt (Paris FRX) Devissaguet Jean-Philippe (Neuilly S/Seine FRX) Puisieux Francis (Maisons Alfort MO FRX) Thies Curt (St. Louis MO), Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles.
Cech Thomas R. (Boulder CO) Zaug Arthur J. (Louisville CO) Been Michael D. (Boulder CO), RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods.
Hirosue Sachiko ; Mueller Bernhard G.,CHX ; Langer Robert S. ; Mulligan Richard C., Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids.
Larry Gold ; Michael Willis ; Tad Koch ; Steven Ringquist ; Kirk Jensen ; Brent Atkinson, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Setterstrom, Jean A.; Tice, Thomas R.; Jacob, Elliot; Reid, Robert H.; van Hamont, John; Boedecker, Edgar C.; Jeyanthi, Ramassubbu; Friden, Phil; Roberts, F. Donald; McQueen, Charles E.; Bhattacharje, Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.